Comparison of two drug-eluting balloons: a report from the SCAAR registry
2012 (English)In: EuroIntervention., ISSN 1774-024X, EISSN 1969-6213, Vol. 8, no 4, 444-449 p.Article in journal (Refereed) Published
Aims: Recently, drug-eluting balloons have received a guideline class IIa recommendation in the treatment of in-stent restenosis after bare metal stent implantation. It is not known if different balloons perform equally. Using a large real world registry, restenosis frequency was reported for two drug-eluting balloons. less thanbrgreater than less thanbrgreater thanMethods and results: From April 2009 until September 2011, 1,129 patients were treated with paclitaxel-eluting balloons in Sweden. Mean follow-up was 328 +/- 210 days. Nine hundred and nineteen patients were treated with a balloon using a contrast agent as a drug-carrier and 217 with a balloon without a contrast agent as a drug-carrier. The indications were predominantly de novo (45.4%) or in-stent restenotic (51.8%) lesions. The overall incidence of restenosis at six months was 3.4% with the paclitaxel balloon using a contrast agent as carrier, compared with 12.5% with the paclitaxel-eluting balloon without a carrier (risk ratio: 0.42; 95% confidence interval [CI] [0.26-0.68]). After adjusting for indications, lesion types and procedural factors, the risk ratio was 0.39; 95% CI (0.24-0.65). less thanbrgreater than less thanbrgreater thanConclusions: This observational study from a large real world population shows a major difference between two paclitaxel-eluting balloons. The findings suggest that there are no class effects for drug-eluting balloons and factors other than the drug may be important for the clinical effect.
Place, publisher, year, edition, pages
Europa Edition , 2012. Vol. 8, no 4, 444-449 p.
drug-eluting balloon, restenosis, in-stent restenosis, paclitaxel, revascularisation
Engineering and Technology
IdentifiersURN: urn:nbn:se:liu:diva-85095DOI: 10.4244/EIJV8I4A70ISI: 000309436400008OAI: oai:DiVA.org:liu-85095DiVA: diva2:564571